$12.69▾ 0.35%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Intellia Therapeutics, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
Aerska Appoints Laura Sepp-Lorenzino to Scientific Advisory Board
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtGene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast